James Saccaro was named Chief Financial Officer and Chief Operating Officer of Zoetis Inc., effective August 17, 2026. As of November 6, 2026, Zoetis Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 22, 2026 to October 13, 2026, naming 2 appointments (Form 8-K, August 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zoetis Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Iris Knobloch · 8-K, 2026-10-13
- · In / out: In · Person: James Saccaro · Role: Chief Financial Officer and Chief Operating Officer · Effective: 2026-08-17 · 8-K, 2026-08-06
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-22
Zoetis Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-22 to 2026-10-13. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Zoetis Inc. files it.
Also on the record for Zoetis Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 30, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 9% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.17% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.7% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 7, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 10.84% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zoetis Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zoetis Inc. and the records around it.
Zoetis Inc. elsewhere on the record
Companies that share a holder
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Zoetis Inc.
Get an email when Zoetis Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zoetis Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Zoetis Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zoetis Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-13 | In | 8-K, 2026-10-13 | |||
| 2026-08-06 | In | Chief Financial Officer and Chief Operating Officer | 2026-08-17 | 8-K, 2026-08-06 | |
| 2026-05-22 | Reported | not named in the filing | 8-K, 2026-05-22 |
Who leads Zoetis Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer and Chief Operating Officer: James Saccaro, appointed, effective 2026-08-17 (filed 2026-08-06).
New leaders reset buying decisions — get the Full Report on Zoetis Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer and Chief Operating Officer at Zoetis Inc., with the record behind each one.
Find candidates like Chief Financial Officer and Chief Operating Officer at Zoetis Inc.Every change, in the filing's words
Appointed: Iris Knobloch
Ms. Knobloch has been appointed to serve on the Board's Corporate Governance Committee.
- On October 8, 2026, the Board of Directors (the "Board") of Zoetis Inc. (the "Company") appointed Iris Knobloch to the Board, effective as of December 1, 2026, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal.
- In connection with the appointment of Ms. Knobloch, the size of the Board will be increased from twelve to thirteen members effective as of December 1, 2026.
- Ms. Knobloch will be eligible for participation in such non-employee director compensation program.
- In connection with her appointment as a member of the Board, the Company will enter into its standard form of indemnification agreement with Ms. Knobloch.
Appointed: James Saccaro, Chief Financial Officer and Chief Operating Officer, effective 2026-08-17
Appointment of James Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer On August 6, 2026, Zoetis Inc. (the "Company") announced that James Saccaro has been appointed as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026.
- Mr. Saccaro will lead Zoetis' global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance.
- He will serve as the principal financial officer and principal accounting officer of the Company.
- Mr. Saccaro, age 53, has served as Vice President and Chief Financial Officer of GE HealthCare Technologies Inc. since June 2023.
- He previously served as Executive Vice President and Chief Financial Officer of Baxter International Inc. from July 2015 to May 2023.
- Mr. Saccaro received a bachelor's degree in economics and master's degree in engineering-economic systems from Stanford University.
- In connection with Mr. Saccaro's appointment, on July 31, 2026, the Company entered into an offer letter with Mr. Saccaro (the "Offer Letter") setting forth the terms of his appointment.
- Mr. Saccaro will also receive a one-time make-whole award of restricted stock units with a grant date value of $6,250,000, which will vest ratably in thirds on the first three anniversaries of the grant date, and a one-time make-whole cash award of $1,250,000, which will be subject to repayment to the Company in the event Mr. Saccaro's employment is terminated under certain circumstances within the first year of employment.
Reported
To elect twelve directors, each to serve for a one-year term until the 2027 Annual Meeting of Shareholders or until each director's successor has been elected and qualified, or until such director's earlier death, resignation or removal. 2.
- At the Annual Meeting, the Company's shareholders voted on five proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2026 (the "Proxy Statement").
- There were 379,034,516 shares of common stock present at the Annual Meeting in person or by proxy, which represented 90.13% of the voting power of the shares of common stock entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business.
- Holders of the Company's common stock were entitled to one vote for each share held as of the close of business on March 27, 2026 (the "Record Date").
- The shareholders of the Company voted on the following proposals at the Annual Meeting: 1.
- A non-binding advisory vote on the compensation program for the Company's named executive officers, as disclosed in the Proxy Statement. 3.
- A non-binding advisory vote on the frequency of future advisory votes on the compensation program for the Company's named executive officers, as disclosed in the Proxy Statement. 4.
- To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. 5.
- To approve a shareholder proposal to permit shareholder action by written consent.
- The voting results for each of these proposals are detailed below. 1.
Tools for this story
Each opens in a new tab, filled in for Zoetis Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.